A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors
Clinical trial NCT04893759 · TERMINATED
Trial details
- NCT number
- NCT04893759
- Sponsor
- Ascentage Pharma Group Inc.
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-06
- Primary completion
- 2022-09-14
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.